{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:57:47Z","timestamp":1772524667868,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010310","name":"E. Matilda Ziegler Foundation for the Blind","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010310","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41433-025-04185-3","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:43:10Z","timestamp":1766749390000},"page":"534-539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ocular adverse effects of bisphosphonates and association with osteonecrosis from a real-world database"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8353-6190","authenticated-orcid":false,"given":"Samuel H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-7078","authenticated-orcid":false,"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-3338","authenticated-orcid":false,"given":"Euna B.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase A.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Lora","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-2242","authenticated-orcid":false,"given":"Karen M.","family":"Wai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"4185_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","volume":"57","author":"DK Wysowski","year":"2013","unstructured":"Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423\u20138. https:\/\/doi.org\/10.1016\/j.bone.2013.09.008.","journal-title":"Bone"},{"key":"4185_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49:20\u201333. https:\/\/doi.org\/10.1016\/j.bone.2011.03.774.","journal-title":"Bone"},{"key":"4185_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.bone.2015.08.020","volume":"81","author":"MK Tsoumpra","year":"2015","unstructured":"Tsoumpra MK, Muniz JR, Barnett BL, Kwaasi AA, Pilka ES, Kavanagh KL, et al. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. Bone. 2015;81:478\u201386. https:\/\/doi.org\/10.1016\/j.bone.2015.08.020.","journal-title":"Bone"},{"key":"4185_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2.","journal-title":"Lancet"},{"key":"4185_CR5","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracturesresults from the fracture intervention trial. JAMA. 1998;280:2077. https:\/\/doi.org\/10.1001\/jama.280.24.2077.","journal-title":"JAMA"},{"key":"4185_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/0140-6736(93)93029-z","volume":"341","author":"ES Siris","year":"1993","unstructured":"Siris ES. Bisphosphonates and iritis. Lancet. 1993;341:436\u20137. https:\/\/doi.org\/10.1016\/0140-6736(93)93029-z.","journal-title":"Lancet"},{"key":"4185_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/s0002-9394(14)72902-2","volume":"118","author":"V Macarol","year":"1994","unstructured":"Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol. 1994;118:220\u20134. https:\/\/doi.org\/10.1016\/s0002-9394(14)72902-2.","journal-title":"Am J Ophthalmol"},{"key":"4185_CR8","doi-asserted-by":"crossref","unstructured":"Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL. Ocular inflammation associated with alendronate therapy. Arch Ophthalmol. 1999;117:837\u20138.","DOI":"10.1001\/archopht.117.6.837"},{"key":"4185_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/jop.2022.0094","volume":"39","author":"NA Chartrand","year":"2023","unstructured":"Chartrand NA, Lau CK, Parsons MT, Handlon JJ, Ronquillo YC, Hoopes PC, et al. Ocular side effects of bisphosphonates: a review of literature. J Ocul Pharmacol Ther. 2023;39:3\u201316. https:\/\/doi.org\/10.1089\/jop.2022.0094.","journal-title":"J Ocul Pharmacol Ther"},{"key":"4185_CR10","doi-asserted-by":"publisher","first-page":"E431","DOI":"10.1503\/cmaj.111752","volume":"184","author":"M Etminan","year":"2012","unstructured":"Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Can Med Assoc J. 2012;184:E431\u20134. https:\/\/doi.org\/10.1503\/cmaj.111752.","journal-title":"Can Med Assoc J"},{"key":"4185_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0b013e31816576ef","volume":"28","author":"DD French","year":"2008","unstructured":"French DD, Margo CE. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina. 2008;28:889\u201393. https:\/\/doi.org\/10.1097\/IAE.0b013e31816576ef.","journal-title":"Retina"},{"key":"4185_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jbmr.1783","volume":"28","author":"M Pazianas","year":"2013","unstructured":"Pazianas M, Clark EM, Eiken PA, Brixen K, Abrahamsen B. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. J Bone Miner Res. 2013;28:455\u201363. https:\/\/doi.org\/10.1002\/jbmr.1783.","journal-title":"J Bone Miner Res"},{"key":"4185_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJM200303203481225","volume":"348","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med. 2003;348:1187\u20138. https:\/\/doi.org\/10.1056\/NEJM200303203481225.","journal-title":"N Engl J Med"},{"key":"4185_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajoc.2019.01.007","volume":"14","author":"M Hassan","year":"2019","unstructured":"Hassan M, Maleki A, Ying Q, Nguyen N, Halim MS, Sepah YJ, et al. Alendronate induced chorioretinitis: the importance of meticulous assessments. Am J Ophthalmol Case Rep. 2019;14:21\u20135. https:\/\/doi.org\/10.1016\/j.ajoc.2019.01.007.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4185_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243\u201353. https:\/\/doi.org\/10.1016\/j.joms.2009.03.050.","journal-title":"J Oral Maxillofac Surg"},{"key":"4185_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ccr3.751","volume":"5","author":"K Yamashiro","year":"2017","unstructured":"Yamashiro K, Sato A, Okazaki F, Nakano M, Sawaki K, Hirata Y, et al. Medication-related osteonecrosis of the jaws caused lethal sepsis in an edentulous patient with multiple systemic factors. Clin Case Rep. 2017;5:97\u2013103. https:\/\/doi.org\/10.1002\/ccr3.751.","journal-title":"Clin Case Rep"},{"key":"4185_CR17","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/cam4.1173","volume":"6","author":"P Corraini","year":"2017","unstructured":"Corraini P, Heide-J\u00f8rgensen U, Schi\u00f8dt M, N\u00f8rholt SE, Acquavella J, S\u00f8rensen HT, et al. Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. Cancer Med. 2017;6:2271\u20137. https:\/\/doi.org\/10.1002\/cam4.1173.","journal-title":"Cancer Med"},{"key":"4185_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RGG Russell","year":"2011","unstructured":"Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49:2\u201319. https:\/\/doi.org\/10.1016\/j.bone.2011.04.022.","journal-title":"Bone"},{"key":"4185_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood.V96.2.384","volume":"96","author":"V Kunzmann","year":"2000","unstructured":"Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384\u201392. https:\/\/doi.org\/10.1182\/blood.V96.2.384.","journal-title":"Blood"},{"key":"4185_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann V, Bauer E, Wilhelm M. \u03b3\/\u03b4 T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737\u20138. https:\/\/doi.org\/10.1056\/NEJM199903043400914.","journal-title":"N Engl J Med"},{"key":"4185_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2353\/ajpath.2007.070008","volume":"171","author":"Z Li","year":"2007","unstructured":"Li Z, Burns AR, Rumbaut RE, Smith CW. Gamma delta T cells are necessary for platelet and neutrophil accumulation in limbal vessels and efficient epithelial repair after corneal abrasion. Am J Pathol. 2007;171:838\u201345. https:\/\/doi.org\/10.2353\/ajpath.2007.070008.","journal-title":"Am J Pathol"},{"key":"4185_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.31083\/j.fbl2904146","volume":"29","author":"Z Sun","year":"2024","unstructured":"Sun Z, Ji H, Zhou Y, Duan H, Ma B, Qi H. Profiles, distribution, and functions of gamma delta T cells in ocular surface homeostasis and diseases. Front Biosci. 2024;29:146. https:\/\/doi.org\/10.31083\/j.fbl2904146.","journal-title":"Front Biosci"},{"key":"4185_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18502\/jovr.v17i1.10176","volume":"17","author":"J Gonzalez Barlatay","year":"2022","unstructured":"Gonzalez Barlatay J, Pagano Boza C, Hernandez Gauna GV, Premoli JE. Orbital inflammation caused by aminobisphosphonates. J Ophthalmic Vis Res. 2022;17:118\u201322. https:\/\/doi.org\/10.18502\/jovr.v17i1.10176.","journal-title":"J Ophthalmic Vis Res"},{"key":"4185_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","volume":"9","author":"P Conte","year":"2004","unstructured":"Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9:28\u201337. https:\/\/doi.org\/10.1634\/theoncologist.9-90004-28.","journal-title":"Oncologist"},{"key":"4185_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","volume":"45","author":"P Lesclous","year":"2009","unstructured":"Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?. Bone. 2009;45:843\u201352. https:\/\/doi.org\/10.1016\/j.bone.2009.07.011.","journal-title":"Bone"},{"key":"4185_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.bonr.2018.03.003","volume":"8","author":"EL George","year":"2018","unstructured":"George EL, Lin Y-L, Saunders MM. Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Rep. 2018;8:104\u20139. https:\/\/doi.org\/10.1016\/j.bonr.2018.03.003.","journal-title":"Bone Rep"},{"key":"4185_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1746-160X-8-5","volume":"8","author":"N Conte-Neto","year":"2012","unstructured":"Conte-Neto N, Bastos AS, Marcantonio RAC, Junior EM. Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws. Head Face Med. 2012;8:5. https:\/\/doi.org\/10.1186\/1746-160X-8-5.","journal-title":"Head Face Med"},{"key":"4185_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1385\/CRIAI:25:1:13","volume":"25","author":"M Abu-Shakra","year":"2003","unstructured":"Abu-Shakra M, Buskila D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol. 2003;25:13\u201324. https:\/\/doi.org\/10.1385\/CRIAI:25:1:13.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4185_CR29","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","volume":"27","author":"J Zhou","year":"2016","unstructured":"Zhou J, Ma X, Wang T, Zhai S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016;27:3289\u20133300. https:\/\/doi.org\/10.1007\/s00198-016-3654-z.","journal-title":"Osteoporos Int"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04185-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04185-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:13:41Z","timestamp":1772522021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04185-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4185"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04185-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}